Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
This article was originally published in The Pink Sheet Daily
Executive Summary
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.
You may also be interested in...
Second Tranche Of $91 Million Venture Round Will Help Advance Two Formulations Of Radius’ Osteoporosis Drug
Radius, which reverse-merged into a public company this past May, has advanced an injectable formulation of BA058 into Phase III, while it is preparing to move a transdermal version into Phase II.
Shire Nabs Advanced BioHealing Before It Can Test the Public Waters
Diversifying further, the specialty outfit will spend $750 million in cash for the regenerative medicine firm and its marketed wound-healing cell therapy product.
Amgen Shifts Its Focus From Products To Pipeline, But Stays In Comfort Zone
Amgen Inc. is sticking to what it knows as it finally moves some of its mid-stage pipeline into later stages. Two of its most promising pipeline candidates, AMG 827 and AMG 785, are intended to be follow-on products to two of Amgen’s biggest franchises: Enbrel (etanercept) and Prolia/Xgeva (denosumab).